Chapter

One Approval That Was Taken Away

From 10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE by 10 Cancer Treatment Approvals From September 2026 and What They Mean for You

Concepts

1. Approval Withdrawal

   "On Sept. 1, the FDA withdrew the accelerated approval of Krazati (adagrasib) plus Erbitux (cetuximab) for KRAS G12C-mutated colorectal cancer after a confirmatory trial did not show that it helped pe

2. Treatment Guidance

   "Krazati is still approved for lung cancer. If you are taking this combination for colorectal cancer, don't stop on your own; talk with your oncologist about next steps."